BIO 300

Drug Profile

BIO 300

Alternative Names: BIO-300

Latest Information Update: 12 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Armed Forces Radiobiology Research Institute; National Institutes of Health (USA)
  • Developer Armed Forces Radiobiology Research Institute; Henry Ford Health System; Humanetics Corporation
  • Class Radioprotectives
  • Mechanism of Action Antioxidants; Apoptosis inhibitors; Haematopoietic cell growth factor stimulants; Protein tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute radiation syndrome
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Radiation injuries
  • Phase I Acute radiation syndrome

Most Recent Events

  • 31 Oct 2017 Humanetics Corporation plans a phase I trial for radiation-induced erectile dysfunction in Prostate cancer (Prevention, Combination therapy) in USA
  • 12 Oct 2017 BIO 300 is still in phase-I/II development for Radiation injuries (Prevention) (in patients with non-small cell lung cancer) in USA (PO) (NCT02567799)
  • 10 Oct 2017 Humanetics receives a Humanetics receives a grant from the National Aeronautics and Space Administration for evaluation of BIO 300 in prevention of radiation induced damage to the cardiac tissue
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top